Zacks: Analysts Anticipate Menlo Therapeutics Inc (NASDAQ:MNLO) Will Announce Earnings of -$0.84 Per Share

Equities analysts expect that Menlo Therapeutics Inc (NASDAQ:MNLO) will report earnings of ($0.84) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Menlo Therapeutics’ earnings, with estimates ranging from ($0.87) to ($0.81). Menlo Therapeutics reported earnings of ($0.36) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 133.3%. The firm is expected to report its next quarterly earnings report on Wednesday, August 7th.

On average, analysts expect that Menlo Therapeutics will report full year earnings of ($3.37) per share for the current fiscal year, with EPS estimates ranging from ($3.52) to ($3.19). For the next fiscal year, analysts forecast that the business will post earnings of ($2.46) per share, with EPS estimates ranging from ($2.87) to ($1.94). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover Menlo Therapeutics.

Menlo Therapeutics (NASDAQ:MNLO) last issued its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.81).

A number of brokerages have recently weighed in on MNLO. Zacks Investment Research downgraded Menlo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 20th. Cantor Fitzgerald reiterated a “buy” rating and set a $25.00 price target on shares of Menlo Therapeutics in a report on Thursday, May 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $17.00.

Shares of NASDAQ MNLO traded up $0.43 during mid-day trading on Friday, reaching $5.99. The company had a trading volume of 630,334 shares, compared to its average volume of 38,282. The stock has a market capitalization of $143.38 million, a PE ratio of -2.53 and a beta of 2.98. The business has a 50-day moving average price of $6.50. Menlo Therapeutics has a 1-year low of $3.74 and a 1-year high of $12.00.

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its holdings in shares of Menlo Therapeutics by 8.9% during the fourth quarter. Bank of America Corp DE now owns 42,160 shares of the company’s stock valued at $173,000 after buying an additional 3,448 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Menlo Therapeutics by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 84,387 shares of the company’s stock valued at $347,000 after buying an additional 3,608 shares in the last quarter. Spark Investment Management LLC grew its holdings in shares of Menlo Therapeutics by 10.7% during the first quarter. Spark Investment Management LLC now owns 50,242 shares of the company’s stock valued at $394,000 after buying an additional 4,842 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Menlo Therapeutics by 18.0% during the first quarter. Acadian Asset Management LLC now owns 42,314 shares of the company’s stock valued at $333,000 after buying an additional 6,459 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Menlo Therapeutics during the fourth quarter valued at $48,000. Institutional investors and hedge funds own 73.95% of the company’s stock.

About Menlo Therapeutics

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough.

Read More: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Menlo Therapeutics (NASDAQ:MNLO)

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.